There has been significant interest in exploring RAF/MEK inhibitors as enhancers of anti-tumor immune responses based on early preclinical studies showing that MEK inhibitors potentiate CD8+ T cell responses by preventing an exhausted phenotype in cancer models, leading to durable responses in combination with PD-L1 inhibitors [115]. Here, MAP2K7 is linked to cancer.